Peter Reichardt

Peter Reichardt

Auto-generated profile, based on publicly available information

Peter Reichardt

HELIOS Klinikum Berlin-Buch Department of Interdisciplinary Oncology Berlin, 13125

Research Focus & Metrics

Academic Career Length

31Years (1996-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2003 in European Journal of Cancer
Verified
Journal Article
Closed access
PRP. Reichardt
P. Reichardt
TLT. Lindner
T. Lindner
DPDaniel Pink
Daniel Pink
PTP.C. Thuss-Patience
P.C. Thuss-Patience
AKA. Kretzschmar
A. Kretzschmar
BDB. Dörken
B. Dörken

15 October 1996
Verified
Journal Article
Closed access
ALA S Lübbe
A S Lübbe
CBC Bergemann
C Bergemann
HRHanno Riess
Hanno Riess
FSF Schriever
F Schriever
PRP Reichardt
P Reichardt
DHD Huhn
D Huhn

1 April 1998 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PRP Reichardt
P Reichardt
JTJ Tilgner
J Tilgner
PHP Hohenberger
P Hohenberger
BDB Dörken
B Dörken
PURPOSE: To evaluate the feasibility and toxicity of the combination of full-dose epirubicin (EPI) and high-dose ifosfamide (IFO) with granulocyte colony-stimulating factor (G-CSF) support and to determine the clinical efficacy in terms of response and impact on survival. PATIENTS AND METHODS: Forty-six consecutive, previously untreated patients with locally advanced or metastatic high-grade soft tissue sarcomas were treated with IFO 2.5 g/m2/d as a continuous infusion on days 1 to 5 and EPI 45 mg/m2/d as a continuous infusion on days 2 and 3 every 3 weeks. G-CSF 5 microg/kg/d subcutaneously (s.c.) was given on days 6 to 15 or until recovery of leukocytes after all cycles. Response evaluation was performed every two cycles and responding patients were treated with up to six cycles. All patients were evaluated for resectability of residual local or metastatic disease and underwent surgery if possible. RESULTS: All patients experienced grade 3 or 4 myelosuppression. Other toxicities were mild. The overall response rate was 52%, with a complete remission (CR) rate of 22% after chemotherapy alone. Eight additional patients were rendered free of tumor (no evidence of disease [NED]) by surgical procedures. The median overall survival of all patients is 24 months. The CR/NED patients (39%) have a significantly superior survival time compared with all other patients. Thirteen of these 18 patients (72%) are alive, nine free of tumor, with a median follow-up time of 33 months. CONCLUSION: This dose-intensive combination chemotherapy is toxic but feasible and produced a high number of partial remissions (PRs) and especially CRs, which resulted in prolonged survival.

4 April 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
HJHeikki Joensuu
Heikki Joensuu
EWEva Wardelmann
Eva Wardelmann
MEMikael Eriksson
Mikael Eriksson
ARAnnette Reichardt
Annette Reichardt
KHKirsten Sundby Hall
Kirsten Sundby Hall
PRPeter Reichardt
Peter Reichardt
Purpose: Limited data are available about the influence of KIT and PDGFRA mutations on overall survival (OS) of patients with gastrointestinal stromal tumor (GIST) treated with adjuvant imatinib. Patients and Methods: The Scandinavian Sarcoma Group XVIII/AIO multicenter trial accrued 400 patients with a high risk for GIST recurrence after macroscopically complete surgery between February 4, 2004, and September 29, 2008. The patients received adjuvant imatinib 400 mg/day for either 1 year or 3 years based on random allocation. We analyzed using conventional sequencing KIT and PDGFRA mutations centrally from 341 (85%) patients who had localized, centrally confirmed GIST, and correlated the results with recurrence-free survival (RFS) and OS in exploratory analyses. Results: During a median follow-up time of 10 years, 164 RFS events and 76 deaths occurred. Most patients were re-treated with imatinib when GIST recurred. Patients with KIT exon 11 deletion or indel mutation treated with 3 years of adjuvant imatinib survived longer than patients treated for 1 year [10-year OS 86% versus 64%, respectively; HR, 0.34; 95% confidence interval (CI), 0.15–0.72; P = 0.007], and also had longer RFS (10-year RFS 47% versus 29%; HR, 0.48; 95% CI, 0.31–0.74; P < 0.001). Patients with KIT exon 9 mutation had unfavorable OS regardless of the duration of adjuvant imatinib. Conclusions: Compared with 1 year of imatinib, 3 years of adjuvant imatinib led to 66% reduction in the estimated risk of death and a high 10-year OS rate in the subset of patients with a KIT exon 11 deletion/indel mutation.

1 July 2021 in European Journal of Cancer
Verified
Journal Article
Open access
IHIvar Hompland
Ivar Hompland
SFStefano Ferrari
Stefano Ferrari
SBStefan S. Bielack
Stefan S. Bielack
Emanuela PalmeriniEmanuela Palmerini
Emanuela Palmerini
KHKirsten S. Hall
Kirsten S. Hall
SSSigbjørn Smeland
Sigbjørn Smeland
The role of chemotherapy for patients with dedifferentiated chondrosarcoma (DDCS) is still under discussion. Here, we present the outcome in patients with DDCS treated with intensive chemotherapy from the EUROpean Bone Over 40 Sarcoma Study. The chemotherapy regimen included doxorubicin, ifosfamide and cisplatin. Postoperative methotrexate was added in case of poor histological response. Toxicity was graded based on the National Cancer Institute expanded common toxicity criteria, version 2.0, and survival was analysed using Kaplan-Meier curves, log-rank tests and univariate Cox regression models. Fifty-seven patients with DDCS (localised, 34 [60%]; metastatic, 23 [40%]) aged 42-65 years were included. Surgical complete remission (SCR) was achieved in 36 (63%) patients. The median overall survival (OS) was 24 months (95% confidence interval, 22-25), and the 5-year OS was 39%. Patients with extremity localisation had a 5-year OS of 49% compared with 29% in patients with a central tumour (P = 0.08). Patients with localised disease had a 5-year OS of 46%, whereas patients with metastatic disease had a 5-year OS of 29% (P = 0.12). Patients in SCR had a 5-year OS of 49%, whereas patients not in SCR had a 5-year OS of 23% (P = 0.004). Chemotherapy toxicity was considerable but manageable. There was no treatment-related death, and 39 (70%) patients received ≥6 cycles of the planned nine chemotherapy cycles. Adding intensive chemotherapy to surgery for treatment of DDCS is feasible and shows favourable survival data compared with previous reports. With the limitations of data from a non-controlled trial, we conclude that chemotherapy could be considered in the management of patients aged >40 years.

13 February 2002 in Critical Reviews in Oncology/Hematology
Verified
Journal Article
Closed access
PRPeter Reichardt
Peter Reichardt